There is no clinically established „cycle length” for CJC-1295 or ipamorelin, and this article does not provide a recommended number of weeks or months for the use of these compounds. This is because no published human studies have tested a long-term standalone protocol for either. What the studies do confirm is a general response regarding timing relative to the body's natural hormonal rhythms, which is discussed further.
How long to use CJC-1295 and ipamorelin?
The honest answer is that this question cannot be answered with a specific duration. Published human studies on CJC-1295 and Ipamorelin were short, controlled scientific studies, not long-term use protocols intended for indefinite use by individuals outside of medical supervision. The main human study for CJC-1295 was organized as two separate studies lasting 28 and 49 days, respectively. Researchers tested single doses and a small number of weekly or bi-weekly repeated doses to observe the hormonal response curve within that timeframe. This was a research design intended to characterize pharmacology—not a demonstration that longer or months-long repeated use is safe or effective [1].
Similarly, the clinical trial of ipamorelin in surgical patients lasted a maximum of seven days or until hospital discharge, reflecting its specific short-term medical goal (assisting gastrointestinal recovery after surgery) rather than an extended wellness or performance enhancement protocol [2].
Since none of these compounds have been studied for months or years of continuous or cyclical human use, there is no scientific basis to state how long someone „should” or safely „can” use them. Any specific duration suggested elsewhere should be considered as not originating from peer-reviewed clinical literature.
How long is the CJC-1295 and ipamorelin cycle?
The concept of a „cycle”—a defined period of use followed by a break—is a commonly adopted framework within bodybuilding and performance enhancement contexts. However, this is not a concept that has been tested or validated in clinical trials in relation to CJC-1295 or ipamorelin. Therefore, no specific cycle lengths, either within this article or in the broader scientific literature, can be presented as evidence-based. The closest available reference points remain the study durations described above: 28–49 days for CJC-1295 in controlled clinical settings [1], and up to seven days for ipamorelin in a hospital-supervised surgical context [2]. Neither of these reflects „cycling” in the bodybuilding sense of repeated on/off periods over an extended duration. No studies have examined what happens with repeated cycling, extended use beyond these windows, or a subsequent „off-cycle” period for either compound.
Reviews covering this category of peptides have specifically noted that details such as treatment duration remain unknown in the clinical literature. This further reinforces the fact that any specific cycle length numbers circulating in commercial or informal sources are not something this article can validate based on actual evidence [3].
When should CJC-1295 be taken?
Although a specific cycle length cannot be provided, there is a scientifically grounded, general principle behind the common suggestion of taking growth hormone-stimulating peptides in the evening or before bed. Growth hormone is naturally released by the body in its largest pulses during deep sleep – a well-established feature of normal human physiology. Aligning administration with the body’s natural nocturnal hormonal rhythm is therefore a sensible and commonly discussed rationale. It is important, however, to maintain precision at this juncture. The primary human studies on CJC-1295 do not specify a particular time of day as part of a validated protocol. The main study focused on measuring the hormone response curve after administration, rather than establishing an optimal time-of-day recommendation [1].
Similarly, ipamorelin pharmacokinetic studies measured a rapid peak—around 40 minutes post-administration—and a short half-life of approximately two hours. This describes how quickly the compound acts after administration but is not in itself a study comparing the outcomes of morning versus evening dosing [4].
While the suggestion of evening timing is therefore logically based on general sleep and growth hormone physiology, it should be understood as an extrapolation from this broader physiological principle – rather than a discovery directly confirmed by specific timing research for either of these compounds.
Limitations of current evidence
The same gap is repeated in all three questions. Clinical trials for CJC-1295 and ipamorelin were designed to characterize short-term hormonal pharmacology, rather than to establish safe or effective patterns of long-term use, cycle length, or optimal dosing timing.
No published studies have tracked outcomes for months of continuous or cyclical use, nor have any studies directly compared different times of day for dosing of either compound. Reviews of this class of peptides consistently identify duration and frequency of use as open, unresolved questions in the literature – rather than established details [3].
Disclaimer
This content is for educational purposes only and does not constitute medical advice, a protocol of use, or a therapeutic recommendation. CJC-1295 and ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. No published human studies have established a safe or effective cycle length, duration of use, or timing protocol for either compound outside of short-term, medically supervised research settings.
References
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
[4] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402